Oh dear,
Chimeric announces intention to undertake Entitlement Offer
• Intention to raise up to approximately $3.2 million at $
0.005 per share on a 2 for 5 basis
• 1 new option (exercise $0.008, expiry 19 December 2025) to be issued for every 1 new
share investors subscribe for (subject to shareholder approval)
• Funds will primarily support continued development of Chimeric’s CHM CDH17 Phase
1/2 clinical trial
• Opportunity for eligible shareholders to participate at the offer price
Melbourne, Australia, 4 March 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”
, an Australian leader in cell therapy, is pleased to announce that it intends to
undertake a pro rata non-renounceable Entitlement Offer to raise up to approximately
$3.2 million (before costs) at an offer price of $0.005 per fully paid ordinary share. This will be
completed on the basis of 2 new shares for every 5 existing shares held by eligible shareholders.
As anticipated by the request for a trading halt on 27 February 2025, the Company had intended
to announce a capital raise. Per the request for voluntary suspension on 3 March 2025, these
discussions were not completed at this time. To lift the voluntary suspension, the Company is
announcing today the intention to undertake an entitlement offer.
(20min delay)